Skip to main content
Investor Center

Imagin Medical Announces Clinical Research Criteria

By 19 October 2017August 26th, 2021No Comments

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company’s initial focus is bladder cancer. 

Vancouver, B.C. and Boston, MA, October 19, 2017 – Imagin Medical, Inc. (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today the recruitment criteria for the upcoming Research Study at the University of Rochester Medical Center. 

The pilot study entitled, Near Infrared Fluorescence Imaging for Bladder Cancer Detection, is sponsored by Dr. Edward Messing, Chair of Urology at the University of Rochester Medical Center, and the study’s principal investigator. The study is registered on the National Institutes of Health (NIH) website www.clinicaltrials.gov. 

Criteria to participate in the study includes men and women 18 years or older, of either sex and any racial or ethnic origin, who are scheduled for a transurethral resection of bladder tumor (TURBT) in the operating room resulting from either a new diagnosis of a potentially malignant bladder mass, or a recurrent tumor. 

The procedure to remove the suspicious mass will remain the same, i.e., TURBT; it is the method to detect the cancerous cells to be removed that will differ significantly. The i/Blue Imaging System is expected to highlight the cancerous cells in less than 10 minutes vs. the full hour required by current systems, leading to a substantial reduction in the time and cost of staff and facilities. 

About Imagin Medical 

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com 

For further information, contact: 

Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: [email protected] 

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions, and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.